Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 19th Global Ophthalmology Summit Berlin, Germany.

Day 1 :

OMICS International Ophthalmology Summit 2018 International Conference Keynote Speaker David W Li photo

David W. Li received his Ph.D. degree in molecular and cellular biology from the University of Washington in Seattle, and completed his postdoctoral training in the Harkness Eye Institute of Columbia Medical Center in New York City. He is currently an elected One-Hundred Talent Professor in the State Key Laboratory of Zhongshan Ophthalmic Center in Sun Yat-sen University


The tumor suppressor p53 plays an essential role in mediating lens differentiation and heterochromatin protection of RPE cells The tumor suppressor, p53 is a multi-function molecule regulating transcription, cell proliferation, differentiation and apoptosis. However, how would p53 regulate lens differentiation remains largely known until our recent demonstration. Oxidative stress (OS)-induced retinal pigment epithelium (RPE) cell apoptosis is critically implicated in the pathogenesis of age-related macular degeneration (AMD), one of the leading causes for blindness in the elderly. The highly condensed, repressive heterochromatin is recently found to play critical roles in mediating diverse stress response. How RPE heterochromatin is regulated upon OS exposure is largely unknown. Here in this lecture, I will discuss our recent work using both mouse model and cultured human RPE cells to investigate how p53 mediates the heterochromatin protection of RPE cells against oxidative damage upon OS exposure.

Keynote Forum

Carl M Sheridan

University of Liverpool, United Kingdom

Keynote: Stem cells and tissue engineering as emerging therapies in ophthalmology
OMICS International Ophthalmology Summit 2018 International Conference Keynote Speaker Carl M Sheridan photo

Carl Sheridan is an internationally renowned cell biologist with research experience in ocular cell biology since 1991. His areas of focus have centered on ocular wound
healing and cell transplantation research with published papers concerning the ocular surface, cornea, outflow pathway as well as retinal pathologies such as proliferative
vitroretinopathy (PVR) and AMD. He has published and reviewed for almost all Ophthalmology scientific journals as well as chaired at international Ophthalmology
conferences. He has a keen interest in both tissue engineering and regenerative medicine approaches to prevent and restore sight loss and is passionate that cross


The eye is a significant focus for advancing regenerative medicine and translational research into human patients. The talk aims
to highlight these by addressing tissue-engineering (TE) approaches for the cornea and retina. New cell-based therapies are
emerging to repair or replace specific cells within the retina. These techniques are at the forefront of human stem cell research
and gene therapy with several phase 1/2 clinical trials currently underway including the first use of iPS cells in human trials.
They offer substantial hope for treating numerous retinal diseases such as Age-related Macular Degeneration. In addition corneal
diseases have often been successfully treated by allogeneic corneal transplantation, yet supply shortage through human donor eye
banks, optical clarity or graft rejection remains a major challenges. Corneal TE research is encompassing scaffolds for stromal and
endothelial transplants, optical transparency or in vivo biocompatibility studies.

Keynote Forum

Shlomo Dotan

Hadassah-Hebrew University Medical Center, Israel

Keynote: Neuro-ophthalmologic diagnoses you do not want to miss

Time : 11:00-11:40

OMICS International Ophthalmology Summit 2018 International Conference Keynote Speaker Shlomo Dotan photo

Born in 1950 in the region of Transylvania, Romania. He Graduated from the Hebrew University – Hadassah Medical School in Jerusalem, Israel in 1974. In 1985 he
finished his residency in Ophthalmology, and in 1990 a fellowship in Neuro-Ophthalmology at the University of Michigan in Ann-Arbor, MI, USA. For the last twenty-
five years is the head of the Neuro-Ophthalmology service at the Hadassah Medical Center in Jerusalem, Israel. In addition to his longstanding clinical work, he has
collaborated internationally with several medical services in research studies, wrote few chapters in medical textbooks, co-authored almost forty articles published in
the international medical literature, lectured in many Ophthalmological & Neuro-Ophthalmological conferences and organized tens of courses along the years in Neuro-

Ophthalmology in various meetings


The presentation will elaborate on twelve neuro-ophthalmologic disorders, part of a longer list, which can potentially cause
death or blindness if not diagnosed and treated correctly
Aneurysmal third nerve palsy. Aneurysm is not the most common compressive lesion causing third nerve palsy, but it has the
highest mortality if untreated. Giant cell arteritis is an idiopathic inflammatory vasculitis affecting small –to-medium size arteries,
which can cause blindness, but also cerebral infarction and cardiac ischemia. Myasthenia gravis is an autoimmune disease of the
neuromuscular junction, which has both an ocular and generalized form. Myasthenic crisis is a neurologic emergency, which
causes paralysis of the muscles of breathing. Pituitary apoplexy results from hemorrhagic infarction of the pituitary gland, and
causes acute endocrine and neurologic symptoms.
Pseudotumor cerebri or idiopathic intracranial hypertension is a condition of unknown cause that produces elevated intracranial
pressure and papilledema primarily in young obese females. In 24% of cases can cause visual dysfunction. Primary optic nerve
sheath meningioma is the most common tumor of the optic nerve sheath, and it typically presents with a slowly progressive optic
neuropathy characterized by a variable loss of visual acuity. Pituitary adenomas are the most common cause of chiasmal lesions
in adults. The most common symptom of a chiasmal compressive lesion is gradual, painless, progressive and bilateral vision loss.
Fungal optic neuropathy may complicate meningitis resulting from a variety of molds and yeasts. The prevalence of these
disorders increases in immunocompromised or immunosuppressed patients with diabetes, lymphoreticular disorders or AIDS.
Neuromyelitis optica or Devic disease is characterized by acute or subacute loss of vision in one or both eyes caused by acute optic
neuropathy preceded or followed within days or weeks by a transverse or ascending myelopathy. Horner syndrome is manifested
with acute neck pain and a miotic pupil. It may be caused by a lesion along the sympathetic pathway that supplies the head, eye
and neck. Toxic/nutritional optic neuropathies usually develop over months with a painless, bilateral, symmetric and progressive
loss of central vision, but some cases may present with acute and severe vision loss such as poisoning with methanol or ethylene
glycol. Transient monocular visual loss lasting minutes in an altitudinal fashion should be considered to be ischemic, due to

cardioembolic source or giant cell arteritis, until proven otherwise

Keynote Forum

Nikoloz Labauri

Davinci Eye Clinic Pvt. Ltd, Georgia

Keynote: 25 Gauge phaco-vitrectomy for retinal detachment

Time : 11:40-12:40

OMICS International Ophthalmology Summit 2018 International Conference Keynote Speaker Nikoloz Labauri photo

More than thousands of Vitreo-Retinal and Cataract surgeries of all complexities. • Hundreds of tube-shunt implantations for Glaucoma, Corneal transplantations and Refractive surgeries. Member of American Society of Retina Specialists ASRS Member of European Society of Cataract & Refractive Surgeons (ESCRS)


Purpose: To compare and evaluate anatomical and functional outcomes of two different surgical techniques to treat hemorrhagic AMD. Methods: The method involved prospective interventional case series. Twelve eyes of 12 patients having subfoveal hemorrhage secondary to wet-AMD were enrolled and divided in two groups. Group 1 includes eight eyes of 8 patients, where PPV was performed. Using 41 Gauge subretinal cannula BSS diluted with tPA (125 mg/ml) was injected to detach the macula. After fluid-air exchange, non-expansile gas was used to fill up only 50% of the vitreous cavity. Group 2 includes four eyes of 4 patients. After PPV peripheral, temporal 200° retinotomy was performed, retina was detached, and free flap was inverted, subfoveal hemorrhage was removed via direct approach and conventional silicone oil tamponade was used. Cases were followed up for 12 months. Results: In Group 1 submacular hemorrhage was successfully displaced inferiorly within 3 days and then completely reabsorbed after few weeks in all 8 cases. The mean VA improved from baseline 0.01 decimals (varied from HM to 0.02) to 0.2 decimals (varied from 0.09 to 0.7) at 12 months. In Group 2 submacular hemorrhage was completely removed in all cases, but mean VA at 12 months was not as high as in Group 1, where mean preoperative VA was 0.01 decimals (varied from HM to 0.03) and mean postoperative VA was 0.05 (varied from HM to 0.1), respectively. No recurrent subfoveal hemorrhage was observed in any group. Subfoveal fibrosis was progressed in 2 out of 8 eyes in Group 1 and 2 out of 4 eyes in Group 2. Significant Optic Nerve atrophy was observed in Group 1 in all cases. This latest can be the main reason why we couldn’t achieve significant improvement of VA in Group 2. Conclusions: This study shows that the technique used in Group one is superior than the technique used in group 2. Thus, minimally invasive procedure should be considered to treat cases of wet AMD complicated with subfoveal hemorrhage.

OMICS International Ophthalmology Summit 2018 International Conference Keynote Speaker Jose Bonifacio Barbosa Jr photo

Dr. Jose Bonifacio Barbosa Jr is currently working as an Ophthalmology Consultant in UDI Hospital, Sao Paulo, Brazil. His research interests include Cornea, Refractive Surgery and Ocular external diseases etc . He is serving as an editorial member and reviewer in several international reputed journals. Dr. Jose Bonifacio Barbosa Jr is also a member of many international affiliations. He has authored many research articles/books related to his Research interest.


Introduction: To compare amniotic membrane transplantation (AMT) associated with narrow-strip conjunctival autograft versus conjunctival autograft alone for the treatment of recurrent pterygium. Methods & Patients: Prospective consecutive interventional study was performed. Patients with recurrent pterygium were randomly divided into one of two groups; group 1: patients undergoing AMT associated with autologous conjunctival graft, and group 2: patients undergoing conjunctival autograft alone. Results: Of the 80 operated eyes included in this study, 39 (Group 1, mean patient age: 52.1±11.7 SD years) underwent AMT associated with narrow-strip conjunctival autograft and 41 (Group 2, mean patient age: 45.8±12.9 SD years) underwent conjunctival autograft alone. In Group 1, 6 eyes (15.4%) had grade-1 pterygium, 19 eyes (48.7%) had grade-2 pterygium, and 14 eyes (35.9%) had grade-3 pterygium. In the second group, 5 eyes (12.2%) had grade-1 pterygium, 18 eyes (43.9%) had grade-2 pterygium, and 14 eyes (35.9%) had grade-3 pterygium. No statistically significant difference was found between the two groups (P=0.752). Of the 39 eyes in Group 1, recurrent pterygium was observed in 7 cases (17.9%). However, of the 41 eyes in Group 2, recurrent pterygium was observed in only 4 cases (9.75%). No statistically significant difference was found between the two groups (P=0.2684). Conclusions: The results of this study indicate that conjunctival autograft alone might be a better surgical choice for the treatment of recurrent pterygia than combining it with AMT, however, this second option provides a good surgical alternative in cases where little conjunctival donor tissue is available. Recent Publications 1. Taylan Sekeroglu H, Erdem E, Dogan N C, Yagmur M, Ersoz R, Dogan A (2011) Sutureless amniotic membrane transplantation combined with narrow-strip conjunctival autograft for pterygium. Int. Ophthalmol. 31(6):433-438. 2. Hirst LW (2009) Recurrent pterygium surgery using pterygium extended removal followed by extended conjunctival transplant: recurrence rate and cosmesis. Ophthalmology. 116(7):1278-1286. 3. Hovanesian J A, Starr C E, Vroman D T, Mah F S, Gomes J A P et. al (2017) Surgical techniques and adjuvants for the management of primary and recurrent pterygia. J. Cataract Refract. Surg. 43(3):405-419. 4. Barbosa Jr. J B, Farias, C C, Hirai F E, Pereira Gomes J A (2017) Amniotic membrane transplantation with narrow strip conjunctival autograft vs. conjunctival autograft for recurrent pterygia. Eur. J. Ophthalmol. 27(2):135-140. 5. Solomon A, Pires R T, Tseng S C (2001) Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. Ophthalmology. 108(3):449-460